Answer:
G1 - S - G2 (may be is option D)
Explanation:
The interface begins with phase G1 where the cell increases its volume and the mass is doubled.
Then, we continue with the S phase where DNA and histones are synthesized.
Afterwardsy we reach the G2 phase where the chromosomes are duplicated.
Finally we reach, the begining of mitosis.
An air-purifying respirator that employs a blower to pump air through filters or cartridges and into the user's breathing zone is known as a powered air-purifying respirator, or PAPR. In comparison to a powered or negative-pressure half mask, this generates a positive pressure inside the facepiece or hood, increasing protection.
<h3>What kind of respirator offers a separate source of clean air?</h3>
For entry into or exit from settings regarded as IDLH, Self-Contained Breathing Apparatus (SCBAs) are employed. They can be either open circuit or closed circuit and contain their own breathing air supply.
<h3>What 2 categories of respirators exist?</h3>
Air-purifying and supplied-air respirators are the two main categories of respirators. Respirators that purify the air remove airborne pollutants such particles, dangerous vapors, and/or gases. They are suitable for use in surroundings with low levels of pollution and in areas with enough oxygen.
<h3>When should you use an air purifying respirator?</h3>
a small, unproven area. a lack of oxygen in the atmosphere. Firefighting. Contaminants with a lower explosive limit (LEL—the concentration at which a gas or vapour could ignite) of at least 20%
learn more about air-purifying respirator here
brainly.com/question/3627134
#SPJ4
Answer:
Thanks for you question. Your hypothesis suggests a linear relationship between serum Cholesterol levels and MI. This hypothesis seems to ignore the difference in the prevalence and effectiveness of LDL receptors in the FH patient.
FH patients who have inherited the mutation from both parents have very few LDL receptors in their blood and therefore almost no ability to pass the unused Cholesterol through the liver. FH patients who are heterozygous will have more LDL receptors although both will find Cholesterol removal problematic without the addition of a PCSK9 inhibitor.
In short, your hypothesis need to account for other factors that are in play.
Explanation:
Consider my case. I am a 64 year old male who has Heterozygous Familial Hypercholesterolemia. Before treatment at age 12 my Total cholesterol was 510 mg/dl. My genetic testing shows two mutations to the LDL Receptor gene with only one mutation being pathogenic. My first heart attack was at 47 and first stroke at 62. My current LDL is too low to detect with the use of a PCSK9 inhibitor (Repatha®).
